相似文献
1
Biomarkers for Immunotherapy Toxicity: Are Cytokines the Answer?
Clin Cancer Res. 2019 Mar 1;25(5):1452-1454. doi: 10.1158/1078-0432.CCR-18-3858. Epub 2018 Dec 26.
2
The determinants of very severe immune-related adverse events associated with immune checkpoint inhibitors: A prospective study of the French REISAMIC registry.
Eur J Cancer. 2021 Nov;158:217-224. doi: 10.1016/j.ejca.2021.08.048. Epub 2021 Oct 7.
3
Predictive and sensitive biomarkers for thyroid dysfunctions during treatment with immune-checkpoint inhibitors.
Cancer Sci. 2020 May;111(5):1468-1477. doi: 10.1111/cas.14363. Epub 2020 Mar 17.
4
Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma.
Ann Oncol. 2021 Jul;32(7):917-925. doi: 10.1016/j.annonc.2021.03.204. Epub 2021 Mar 30.
5
Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
Front Oncol. 2021 Nov 26;11:749064. doi: 10.3389/fonc.2021.749064. eCollection 2021.
6
Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy.
Int J Mol Sci. 2023 Feb 1;24(3):2769. doi: 10.3390/ijms24032769.
7
Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines.
Trends Immunol. 2021 Apr;42(4):293-311. doi: 10.1016/j.it.2021.02.006. Epub 2021 Mar 10.
8
Immunogenomic correlates of immune-related adverse events for anti-programmed cell death 1 therapy.
Front Immunol. 2022 Nov 25;13:1032221. doi: 10.3389/fimmu.2022.1032221. eCollection 2022.
9
Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors.
J Transl Med. 2018 Apr 2;16(1):82. doi: 10.1186/s12967-018-1452-4.
10
Interleukin-10 Is a Promising Marker for Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer Receiving Immunotherapy.
Front Immunol. 2022 Feb 9;13:840313. doi: 10.3389/fimmu.2022.840313. eCollection 2022.
引用本文的文献
1
Predictive capacity of immune-related adverse events and cytokine profiling in neoadjuvant immune checkpoint inhibitor trials for head and neck squamous cell carcinoma.
Cancer Med. 2024 Jun;13(11):e7370. doi: 10.1002/cam4.7370.
2
Biomarkers of immune checkpoint inhibitor response and toxicity: Challenges and opportunities.
Immunol Rev. 2023 Sep;318(1):157-166. doi: 10.1111/imr.13249. Epub 2023 Jul 20.
3
A case report and literature review of immune checkpoint inhibitor-associated pneumonia caused by penpulimab.
Front Immunol. 2023 Jun 22;14:1114994. doi: 10.3389/fimmu.2023.1114994. eCollection 2023.
4
First-Line Immunotherapy with Check-Point Inhibitors: Prospective Assessment of Cognitive Function.
Cancers (Basel). 2023 Mar 6;15(5):1615. doi: 10.3390/cancers15051615.
5
Immune checkpoint inhibitor-induced myocarditis with myasthenia gravis overlap syndrome: A case report and literature review.
Medicine (Baltimore). 2022 Dec 9;101(49):e32240. doi: 10.1097/MD.0000000000032240.
6
Safety and efficacy of immune checkpoint inhibitors in non-small cell lung cancer patients with preexisting antinuclear antibodies: a retrospective cohort study.
Transl Lung Cancer Res. 2022 Jul;11(7):1420-1433. doi: 10.21037/tlcr-22-464.
7
Immune checkpoint inhibitor-related interstitial lung disease in patients with advanced non-small cell lung cancer: systematic review of characteristics, incidence, risk factors, and management.
J Thorac Dis. 2022 May;14(5):1684-1695. doi: 10.21037/jtd-22-93.
8
Development and Validation of a Radiomics Nomogram Using Computed Tomography for Differentiating Immune Checkpoint Inhibitor-Related Pneumonitis From Radiation Pneumonitis for Patients With Non-Small Cell Lung Cancer.
Front Immunol. 2022 Apr 26;13:870842. doi: 10.3389/fimmu.2022.870842. eCollection 2022.
9
The current landscape of immunotherapy for pediatric brain tumors.
Nat Cancer. 2022 Jan;3(1):11-24. doi: 10.1038/s43018-021-00319-0. Epub 2022 Jan 20.
10
Crossed Pathways for Radiation-Induced and Immunotherapy-Related Lung Injury.
Front Immunol. 2021 Dec 1;12:774807. doi: 10.3389/fimmu.2021.774807. eCollection 2021.
本文引用的文献
1
Circulating Cytokines Predict Immune-Related Toxicity in Melanoma Patients Receiving Anti-PD-1-Based Immunotherapy.
Clin Cancer Res. 2019 Mar 1;25(5):1557-1563. doi: 10.1158/1078-0432.CCR-18-2795. Epub 2018 Nov 8.
2
Immune Checkpoint Inhibitor Toxicity in 2018.
JAMA. 2018 Oct 23;320(16):1702-1703. doi: 10.1001/jama.2018.13995.
3
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
JAMA Oncol. 2018 Dec 1;4(12):1721-1728. doi: 10.1001/jamaoncol.2018.3923.
4
Biomarkers for immune-related toxicities of checkpoint inhibitors: current progress and the road ahead.
Expert Rev Mol Diagn. 2018 Mar;18(3):297-305. doi: 10.1080/14737159.2018.1440209. Epub 2018 Feb 15.
5
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade.
N Engl J Med. 2018 Jan 11;378(2):158-168. doi: 10.1056/NEJMra1703481.
6
Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders.
JAMA Oncol. 2016 Feb;2(2):234-40. doi: 10.1001/jamaoncol.2015.4368.
Zotero 插件